Oral immunotherapy isn't a miracle cure. It can help individuals with peanut allergies successfully consume one peanut. That might not sound like a lot, but it can make a life-changing…... Read more

There’s not much hope for a bipartisan drug pricing compromise in Washington. Instead, Democrats are using their marquee drug bill as a weapon on the 2020 campaign trail... Read more

An investigation identified for the first time pharmaceutical companies whose factories are likely dumping substantial quantities of drugs into rivers and streams.... Read more

Uniqure and Pfizer are advancing toward market one-time treatments for the blood-clotting disorder, with Takeda about to begin clinical testing of its own therapy. ... Read more

A strong emphasis on primary care across our health care system and continued benchmarking of U.S. health care performance against that of other wealthy nations will point us to a…... Read more

So what are fast-growing tech and biotech companies doing to fill open jobs in the waning days of 2019?... Read more

The newly unveiled trade deal doesn't include any protections for high-tech biologic drugs.... Read more

As its new CEO begins to move Sanofi away from new diabetes research, the drugmaker—and producer of one of the world’s top-selling insulins—will also look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.... Read more

"We've been slow. We haven't empowered enough," CEO Paul Hudson said Tuesday in rolling out his strategy for the French pharma.... Read more

While the FDA had 190 inspectors in the U.S. who conducted most foreign inspections, another 58 positions were vacant.... Read more

When Novartis unveiled its $9.7 billion buyout of The Medicines Company a few days ago, several industry watchers suggested the price was too high. Turns out, Novartis' own number-crunching "could not justify $85 per share" for the PCSK9 drug developer, SEC documents show—but even so, the company at one point... Read more

NASH leaders, including Genfit, Intercept Pharmaceuticals, Gilead and NGM Biopharmaceuticals, discuss why we need a drug for the disease and the challenges companies and doctors face in diagnosing and treating patients.... Read more

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab. The company has long been a leader in diabetes and cardiovascular diseases, but it won't be focused there going forward. Instead, it's focusing on rare... Read more

Christi Shaw, who was named CEO of Kite five months ago, sees opportunities for the cellular therapies in new cancer types and earlier treatment settings.... Read more

Merck's surprise buyout of ArQule will heat up competition in a class of cancer drugs that includes AbbVie and J&J's Imbruvica and AstraZeneca's Calquence.... Read more